Skip to Main Content

Paper Details

Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia.
Nat Commun
6
2022
-rearranged ALL cells, ALL, ALL cell, FLT3, FLT3 gene, FLT3 locus, ZNF384, ZNF384 binding sites, ZNF384-, ZNF384-rearranged ALL, ZNF384-rearranged ALL cells, active enhancers, acute lymphoblastic leukemia, cancer, gilteritinib, intergenic enhancer element, leukemia, patient, patient-
Author NameAffiliation
Kristine R CrewsDepartment of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital
Chia-Lin Wei
Ching-Hon PuiSt. Jude Children's Research Hospital
  • 1 - 3

Datasets

Release 1.2